Oral Cancer

P=N/A, N=30, Active, not recruiting, Alpha Tau Medical LTD. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Bioinformatic analyses further indicated that the rs4274 A allele is associated with increased MIAT expression, and higher MIAT levels correlated with higher tumor grade. In conclusion, the MIAT rs4274 A allele is linked to poorer tumor differentiation, particularly among betel-quid chewers and smokers, and elevated MIAT expression supports its potential as a biomarker of tumor aggressiveness.

Herbal agents and combination therapies, such as those containing β-carotene, isotretinoin, IFN-α 2a, and vitamin E, have shown encouraging results, although the long-term benefits remain uncertain...While chemopreventive strategies offer potential, their clinical application remains limited by inconsistent outcomes and adverse effects. Advancing this field requires the development of targeted therapies, personalised approaches based on molecular profiling, and innovative delivery systems like nanocarriers to improve therapeutic efficacy and safety.

Centering this chemo-photodynamic-immunotherapeutic cascade on enhanced ROS, ID-TEX concurrently improves efficacy, reduces toxicity, and strengthens immune modulation, underscoring strong translational potential for precision OSCC therapy.

P=N/A, N=20, Not yet recruiting, National Taiwan University Hospital

P=N/A, N=1120, Active, not recruiting, International Agency for Research on Cancer | Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> Jan 2026

IL-17 inhibitor administration is associated with an elevated incidence of oral complications, particularly oral candidiasis and herpetic infections, highlighting the importance of clinician awareness and assessment of oral complications during IL-17 inhibitors therapy.

Sanye green extract can inhibit OSCC cell proliferation and invasion, promote its apoptosis. Its mechanism of action may be related to the regulation of NLRP3/PRKD3 expression.

Mechanistically, the uptake of prostaglandin E synthase (PTGES)-enriched migrasomes by macrophages increases PTGES expression and prostaglandin E2 secretion, which in turn induces an SPP1+ macrophage phenotype and promotes migration and proliferation. These findings uncover an unexplored migrasome-dependent immunomodulatory mechanism in OLK carcinogenesis and suggest migrasomal PTGES as a promising biomarker for early OSCC detection and a potential therapeutic target.

This prospective real-world analysis shows slightly shorter median PFS and OS times compared with the pivotal trials. Patients in our analyses received alpelisib in later therapy lines, which may explain the poorer outcome.

Because this pathway is readily inhibited by common nonsteroidal anti-inflammatory drugs (NSAID), the findings support clinical evaluation of combined metformin and NSAID therapy to improve HNSCC chemoprevention. See related article by Hoang et al., p. 79 .

GOLM1 is overexpressed in OSCC tissues and cells, and silencing of this protein inhibits OSCC cell proliferation, migration, invasion, and EMT via the TGF-β1/Smad2 signaling pathway.